Cargando…

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis

INTRODUCTION: Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart insulin pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs and expected health outcomes, this analysis evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jendle, Johan, Ericsson, Åsa, Gundgaard, Jens, Møller, Jonas Bech, Valentine, William J., Hunt, Barnaby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843677/ https://www.ncbi.nlm.nih.gov/pubmed/33306169 http://dx.doi.org/10.1007/s13300-020-00980-1

Ejemplares similares

Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden
por: Jendle, Johan, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden
por: Jendle, Johan, et al.
Publicado: (2017)

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
por: Andersson, Emelie, et al.
Publicado: (2020)

Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen
por: Adolfsson, Peter, et al.
Publicado: (2020)

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
por: Ericsson, Åsa, et al.
Publicado: (2017)

Improved Glycemic Control Observed in Children with Type 1 Diabetes Following the Introduction of Smart Insulin Pens: A Real-World Study
por: Adolfsson, Peter, et al.
Publicado: (2021)

Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
por: Hunt, Barnaby, et al.
Publicado: (2019)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Cost-Effectiveness of the FreeStyle Libre(®) System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden
por: Jendle, Johan, et al.
Publicado: (2021)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
por: Evans, Marc, et al.
Publicado: (2016)

Potential cost savings in the United States from a reduction in sensor-detected severe hypoglycemia among users of the InPen smart insulin pen system
por: Chien, Albert, et al.
Publicado: (2023)

InPen Smart Insulin Pen System: Product Review and User Experience
por: Gildon, Bradford W.
Publicado: (2018)

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
por: Evans, Marc, et al.
Publicado: (2018)

IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting
por: Hunt, Barnaby, et al.
Publicado: (2017)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
por: Evans, Marc, et al.
Publicado: (2020)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
por: Pollock, Richard F., et al.
Publicado: (2018)

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
por: Hunt, Barnaby, et al.
Publicado: (2017)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
por: Pollock, Richard F., et al.
Publicado: (2019)

The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden
por: Jendle, Johan, et al.
Publicado: (2021)

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
por: Hunt, Barnaby, et al.
Publicado: (2017)

Digital Diabetes Management: A Literature Review of Smart Insulin Pens
por: Heinemann, Lutz, et al.
Publicado: (2021)

The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs
por: Kotsopoulos, Nikolaos, et al.
Publicado: (2022)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Estimating the impact of changes in HbA(1c), body weight and insulin injection regimen on health related quality-of-life: a time trade off study
por: Ridderstråle, Martin, et al.
Publicado: (2016)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

A Comparison of Insulin Pen Devices and Disposable Plastic Syringes – Simplicity, Safety, Convenience and Cost Differences
por: Singh, Ripudaman, et al.
Publicado: (2018)

Smart Connected Insulin Pens, Caps, and Attachments: A Review of the Future of Diabetes Technology
por: Sangave, Nikhil A., et al.
Publicado: (2019)

Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
por: Hunt, Barnaby, et al.
Publicado: (2017)

Shunt surgery in iNPH patients is cost-effective – a cost-utility analysis in the Western Sweden setting
por: Tullberg, Mats, et al.
Publicado: (2015)

Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries
por: Roze, Stéphane, et al.
Publicado: (2012)

Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
por: Kvapil, Milan, et al.
Publicado: (2017)

ElectroPen: An ultra-low–cost, electricity-free, portable electroporator
por: Byagathvalli, Gaurav, et al.
Publicado: (2020)

Costs of Informal Care for People Suffering from Dementia: Evidence from a Danish Survey
por: Jakobsen, Marie, et al.
Publicado: (2011)

Costs of shoulder pain and resource use in primary health care: a cost-of-illness study in Sweden
por: Virta, Lena, et al.
Publicado: (2012)

Atrial fibrillation: the cost of illness in Sweden
por: Ericson, Lisa, et al.
Publicado: (2010)

The societal costs of problem gambling in Sweden
por: Hofmarcher, T., et al.
Publicado: (2020)

A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden
por: Jendle, J., et al.
Publicado: (2022)

An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen(®)
por: Davis, Estella M, et al.
Publicado: (2010)

Low-cost smart antennas
por: Luo, Qi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r68a3v0bfab810pm6iikcabjpe